Abstract
Nurse monitors collected clinical and laboratory data from 204 hospitalized patients receiving furosemide (122 men and 82 women; mean age 69.6 years). Biochemical abnormalities and clinical problems definitely or probably induced by any drug occurred in 70.6% and 49.0% respectively of the patients, and were attributed to furosemide in 81.3% and 13.0% respectively of these patients. The most important clinical events were dehydration and hypotension. Furosemide-induced hypochloremia, hypokalemia and hyponatremia occurred in 35.8%, 25.0% and 24.5% of the patients respectively. Most of the biochemical changes were slight, and only 3.9% of the patients had a furosemide-induced decrease in the serum potassium concentration to less than 3.0 mmol/L. Surprisingly, 24.5% of the patients also manifested drug-induced hyperkalemia. Administration potassium supplements or spironolactone, or both, concurrently with furosemide was responsible in most cases for the development of hyperkalemia. The occurrence of drug-induced adverse effects after 2 weeks of hospitalization was significantly associated (P less than 0.05) with subsequent prolongation of hospitalization. The high frequency of drug-induced events warrants careful monitoring of all patients receiving furosemide in spite of the low frequency of serious toxic effects produced by the drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cooperman L. B., Rubin I. L. Toxicity of ethacrynic acid and furosemide. Am Heart J. 1973 Jun;85(6):831–834. doi: 10.1016/0002-8703(73)90434-1. [DOI] [PubMed] [Google Scholar]
- Gray T. K., Adams L. L., Fallon H. J. Short-term intense surveillance of adverse drug reactions. J Clin Pharmacol New Drugs. 1973 Feb-Mar;13(2):61–67. doi: 10.1002/j.1552-4604.1973.tb00254.x. [DOI] [PubMed] [Google Scholar]
- Greenblatt D. J., Duhme D. W., Allen M. D., Koch-Weser J. Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J. 1977 Jul;94(1):6–13. doi: 10.1016/s0002-8703(77)80337-2. [DOI] [PubMed] [Google Scholar]
- Hurwitz N., Wade O. L. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1969 Mar 1;1(5643):531–536. doi: 10.1136/bmj.1.5643.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karch F. E., Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975 Dec 22;234(12):1236–1241. [PubMed] [Google Scholar]
- Kim K. E., Onesti G., Moyer J. H., Swartz C. Ethacrynic acid and furosemide. Diuretic and hemodynamic effects and clinical uses. Am J Cardiol. 1971 Apr;27(4):407–415. doi: 10.1016/0002-9149(71)90438-3. [DOI] [PubMed] [Google Scholar]
- Mahabir R. N., Bacchus R. Diuretic and clinical effects of low-dose furosemide in congestive heart failure patients. J Clin Pharmacol. 1976 Oct;16(10 Pt 1):510–517. [PubMed] [Google Scholar]
- Ogilvie R. I., Ruedy J. Adverse reactions during hospitalization. Can Med Assoc J. 1967 Dec 9;97(24):1445–1450. [PMC free article] [PubMed] [Google Scholar]
- Smith J. W., Seidl L. G., Cluff L. E. Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility. Ann Intern Med. 1966 Oct;65(4):629–640. doi: 10.7326/0003-4819-65-4-629. [DOI] [PubMed] [Google Scholar]
- Stason W. B., Cannon P. J., Heinemann H. O., Laragh J. H. Furosemide. A clinical evaluation of its diuretic action. Circulation. 1966 Nov;34(5):910–920. doi: 10.1161/01.cir.34.5.910. [DOI] [PubMed] [Google Scholar]